All Comments by Takaomi Saido

  1. Lack of brain-to-blood efflux transport activity of low-density lipoprotein receptor-related protein-1 (LRP-1) for amyloid-beta peptide(1-40) in mouse: involvement of an LRP-1-independent pathway.
  2. Structure-neurotoxicity relationships of amyloid beta-protein oligomers.
  3. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.
  4. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.
  5. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta.
  6. Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis.
  7. The amyloid-beta rise and gamma-secretase inhibitor potency depend on the level of substrate expression.
  8. Human membrane metallo-endopeptidase-like protein degrades both beta-amyloid 42 and beta-amyloid 40.
  9. Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106.
  10. ATP-binding cassette transporter G4 is highly expressed in microglia in Alzheimer's brain.
  11. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin.
  12. Beta-amyloid peptide stimulates endozepine release in cultured rat astrocytes through activation of N-formyl peptide receptors.
  13. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease.
  14. Biochemical markers in persons with preclinical familial Alzheimer disease.
  15. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.